Last reviewed · How we verify
SV-BR-1-GM
SV-BR-1-GM is an autologous breast cancer immunotherapy that uses patient-derived dendritic cells loaded with breast cancer-associated antigens to stimulate anti-tumor immune responses.
SV-BR-1-GM is an autologous breast cancer immunotherapy that uses patient-derived dendritic cells loaded with breast cancer-associated antigens to stimulate anti-tumor immune responses. Used for Breast cancer (Phase 3 development).
At a glance
| Generic name | SV-BR-1-GM |
|---|---|
| Also known as | Part of the Bria-IMT regimen |
| Sponsor | BriaCell Therapeutics Corporation |
| Drug class | Autologous dendritic cell vaccine |
| Target | Breast cancer-associated antigens (patient-specific) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
The drug is a personalized cancer vaccine composed of dendritic cells derived from the patient's own immune system, which are ex vivo loaded with lysate from the patient's own breast cancer tissue. These antigen-loaded dendritic cells are then reinfused to prime and activate the patient's T cells against breast cancer-specific antigens, generating a targeted anti-tumor immune response.
Approved indications
- Breast cancer (Phase 3 development)
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- Combination Study of SV-BR-1-GM With Retifanlimab (PHASE1, PHASE2)
- Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (PHASE3)
- Allogeneic, Antigen-Presenting, GM-CSF-secreting, SV-BR-1-GM Whole Cell-Therapeutic Vaccine and Immunotherapy: A Phase I Pilot Safety and Feasibility Study for Solid Tumor Patients With CNS Metastases (PHASE1)
- Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer (PHASE1, PHASE2)
- A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer (PHASE1, PHASE2)
- SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |